Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN11752770
ISRCTN11752770
Active, not recruiting
未知

A single arm study investigating the feasibility of a clinician guided online pain management programme for people with chronic pain conditions

My Pain Ltd0 sites15 target enrollmentSeptember 16, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
My Pain Ltd
Enrollment
15
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 16, 2015
End Date
June 30, 2022
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
My Pain Ltd

Eligibility Criteria

Inclusion Criteria

  • •1\. Over 18 years of age
  • •2\. Diagnosed with a chronic pain condition for at least 6 months
  • •3\. If medicated for anxiety or depression, on a stable dose of medication as defined by no change in medication dose for 1 month or more
  • •4\. Full capacity to consent
  • •5\. Has regular access to the Internet and a smartphone / tablet / computer
  • •6\. Prepared and comfortable to regularly interface with a treatment modality primarily delivered through online methods including mobile devices
  • •7\. Able to understand the contents and participate in the language of the programme (English only)

Exclusion Criteria

  • •1\. People with an unstable mental health condition as determined by assessing clinician or GP
  • •2\. People with severe symptoms of depression \>20 on Patient Health Questionnaire (PHQ\-9\) or suicidal/self\-harming thoughts experienced more than half the days in the previous 2 weeks
  • •3\. People who already score highly on self\-efficacy; 50 or more on the Pain Self Efficacy Scale (PSEQ; see outcomes section)
  • •4\. People with chronic headache, autoimmune diseases, malignant cancer pain, and facial pain
  • •5\. Participating in any psychological therapy for any condition at the point of recruitment
  • •6\. Previously accessed cognitive behavioural pain management

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Technology Assisted Dietary Assessment and Advice (TADAA) Feasibility StudyCardiovascular diseaseCardiovascular - Coronary heart diseaseDiet and Nutrition - Other diet and nutrition disorders
ACTRN12623001084673Edith Cowan University30
Unknown
Not Applicable
Imaging glioblastoma pH using CEST-MRIBrain CancerCancerMalignant neoplasm of brain
ISRCTN86522205niversity of Oxford19
Recruiting
Not Applicable
An open-label, single-arm study to investigate the efficacy of Favipiravir on Lassa Fever for Post Exposure Prophylaxisassa fever
JPRN-jRCTs031230118Morioka Shinichiro5
Active, not recruiting
Phase 1
A study to understand disease biology and to test the effect and safety of inhaled nemiralisib in adult patients with APDS
EUCTR2015-004876-31-GBGlaxoSmithKline Research & Development Ltd20
Active, not recruiting
Phase 1
Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuPyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.MedDRA version: 20.0Level: PTClassification code 10037635Term: Pyoderma gangrenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2015-000762-65-DETechnische Universität München, School of Medicine, represented by Dean7